Zevra Therapeutics (ZVRA) Superinvestor holders
12 of the superinvestors we track hold Zevra Therapeutics (ZVRA) in their latest 13F filings, $86M in total.
Summary
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $26M, 1.6% of the portfolio.
In their latest quarter: 3 opened a new position, 4 added, 4 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management |
Trimmed | 1,797,476 | $26M | 1.6% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 1,306,949 | $19M | 0.0% | Q2 2026 |
| Mark Kingdon Kingdon Capital Management |
Held | 775,000 | $11M | 1.5% | Q2 2026 |
| Chuck Royce Royce Investment Partners |
Added | 909,137 | $10M | 0.1% | Q3 2026 |
| Arrowstreet Capital | New position | 597,162 | $9M | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Trimmed | 415,058 | $6M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 190,972 | $3M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 70,286 | $1M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 65,208 | $935,083 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
New position | 32,190 | $351,000 | 0.0% | Q3 2026 |
| Alan Howard Brevan Howard |
Trimmed | 21,730 | $311,608 | 0.0% | Q2 2026 |
| Ken Tropin Graham Capital Management |
New position | 11,764 | $168,696 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 10 |
| Q4 2025 | 11 |
| Q3 2025 | 11 |
| Q2 2025 | 3 |
| Q1 2025 | 3 |
| Q4 2024 | 3 |
| Q3 2024 | 2 |
Questions about Zevra Therapeutics
Which superinvestors own Zevra Therapeutics?
12 of the superinvestors we track hold Zevra Therapeutics (ZVRA) in their latest 13F filings, $86M in total. Wilmot Harkey, David Shaw, Mark Kingdon, Chuck Royce, Arrowstreet Capital, Paul Tudor Jones.
Who is the largest superinvestor holder of ZVRA?
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $26M, 1.6% of the portfolio.
From Zevra Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.